Dr. Kunimoto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2152 S Vineyard
Ste 136
Mesa, AZ 85210Phone+1 602-858-3690
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 2001 - 2004
Massachusetts General HospitalInternship, Internal Medicine, 1999 - 2000
Harvard Medical SchoolClass of 1999
Certifications & Licensure
AZ State Medical License 2006 - 2026
HI State Medical License 2005 - 2026
CA State Medical License 2015 - 2025
PA State Medical License 2001 - 2006
DE State Medical License 2002 - 2002- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus Start of enrollment: 2012 Nov 01
- Telescope Exchange Study Start of enrollment: 2017 Mar 22
- The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Start of enrollment: 2019 Nov 15
Publications & Presentations
PubMed
- 3 citationsPolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular ...Sheri L Peterson, Anitha Krishnan, Diyan Patel, Ali Khanehzar, Amit Lad
Pharmaceuticals. 2024-04-17 - 1 citationsComprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-...Anitha Krishnan, David G Callanan, Victor G Sendra, Amit Lad, Sunny Christian
Pharmaceuticals. 2024-04-09 - 22 citationsTwo-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.Rahul N. Khurana, Derek Y Kunimoto, Young Hee Yoon, Charles C. Wykoff, Andrew Chang
Ophthalmology. 2021-07-01
Authored Content
- Efficacy and Safety of Abicipar in Neovascular Age‐Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled StudyApril 2020
Press Mentions
Aviceda Therapeutics Announces Formation of Executive TeamJanuary 11th, 2021
Telescope Implanted in Eye Helps Thousands of Arizonans SeeNovember 7th, 2015
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
